Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients

Indian Journal of Medical Research

Volumn 130, Issue 5, 2009, Pages 533-541

  Bolhassani, Azam ^a,b   Zahedifard, Farnaz ^a   Taslimi, Yasaman ^a   Taghikhani, Mohammad ^b   Nahavandian, Bijan ^c   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cervical cancer; E7; GP96; HPV; Serological marker

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN GP 96; HISTAMINE; PROTEIN ANTIBODY; PROTEIN E7; RECOMBINANT PROTEIN;

ADENOCARCINOMA; AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IRAN; MAJOR CLINICAL STUDY; SEROLOGY; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WESTERN BLOTTING;

ADULT; AGED; ANTIBODIES, NEOPLASM; ANTIBODIES, VIRAL; BASE SEQUENCE; DNA PRIMERS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IRAN; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PAPILLOMAVIRUS E7 PROTEINS; RECOMBINANT PROTEINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 72449179014     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol 2004; 15: 197-200.
2. Meschede W, Zumbach K, Pawlita M. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998; 36: 475-80.
3. Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB. CD4- positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol 1999; 6: 494-8.
4. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus 16E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
5. Mirecka EA, Rudolph R, Hey T. Expression and Purification of His-tagged HPV16E7 protein active in pRb binding. Protein Expression and Purification 2006; 48: 281-91.
6. Fernando G, Murray B, Zhou J, Frazer I. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999; 115: 397-403.
7. Bleul C, Muller M, Frank R, Gissmann L. Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. J Clin Microbiol 1991; 29: 1579-88.
8. Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E, et al. Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 2003; 188: 49-55.
9. Zumbach K, Kisseljov F, Sacharova O, Shaichaev G, Semjonova L, Pavlova L, et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer 2000; 85: 313-8.
10. Silins I, Avall-Lundqvist E, Tadesse A, Jansen KU, Stendahl U, Lenner P, et al. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol 2002; 85: 333-8.
11. Rosales R, López-Contreras M, Cortes RR. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA. J Med Virol 2001; 65: 736-44.
12. Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, et al. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Arch Virol 2006; 151: 1899-916.
13. Robert J, Menoret A, Cohen N. Cell surface expression of the endoplasmic reticular heat shock protein gp96 is phylogenetically conserved. J Immunol 1999; 163: 4133-9.
14. Robert J, Gantress J, Cohen N, Maniero GD. Xenopus as an experimental model for studying evolution of hsp immune system interactions. Methods 2004; 32: 42-53.
15. Robert J, Cohen N, Maniero GD, Goyos A, Morales H, Gantress J. Evolution of the immunomodulatory role of the heat shock protein gp96. Cell Mol Biol 2003; 49: 263-75.
16. Zugel U, Kaufmann S. Role of heat shock proteins in protection from and pathogenesis of infectious disease. Clin Microbiol Rev 1999; 12: 19-39.
17. Chen CH, Wang TL, Hung CF, Yang Y, Pardoll DM, Wu TC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 1035-42.
18. Rapp U, Kaufmann S. DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 2004; 16: 597-605.
19. Hauser H, Chen SY. Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 2003; 31: 225-31.
20. Robert J. Evolution of heat shock protein and immunity. Dev Comp Immunol 2003; 27: 449-64.
21. Li H, Zhou M, Han J, Zhu X, Tien P. Generation of murine CTL by a Hepatitis B virus- specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005; 174: 195-204.
22. Meng SD, Song J, Rao Z, Tien P, Gao G. Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides. J Immunol Methods 2002; 264: 29-35.
23. Warger T, Hilf N, Radsak MP, Schild H. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 2004; 281: 2 2545-53.
24. Sambrook J, Russell DW. Molecular cloning. A laboratory manual. 3rd ed. New York: Cold Spring Harbor; 2001. p. 8.18-8.96.
25. Harlow E, Lane D. Antibodies. A laboratory manual. 1st ed. New York: Cold Spring Harbor; 1998. p. 471-511.
26. Armstrong DJ, Roman A. The anomalous electrophoretic behavior of the human papillomavirus type 16 E7 protein is due to the high content of acidic amino acid residues. Biochem Biophys Res Commun 1993; 192: 1380-7.
27. Kim TY, Myoung HJ, Kim JH, Moon IS, Ahn WS, Sin JI. Both E7 and CpG-Oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 2002; 62: 7234-40.
28. Pagliusi SR, Garland SM. International standard reagents for HPV detection. Dis Markers 2007; 23: 283-96.
29. Biswas C, Sriram U, Argon Y. The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen presenting cells. Int Immunol 2006; 18: 1147-57.
30. Dai J, Liu B, Caudill MM, Zheng H, Podak ER, Li Z. Cell surface expression of heat shock protein gp96 enhances cross- presentation of cellular antigens and the generation of tumor- specific T cell memory. Cancer Immun 2003; 3: 1-11.
31. Chandawarkar RY, Wagh MS, Kovalchin JT, Srivastava P. Immune modulation with high- dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int Immunol 2004; 16: 615-24.
32. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
33. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 2001; 164: 1151-2.
34. Andersson S, Larson B, Hjerpe A, Silfversward C, Sallstrom J, Wilander E, et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand 2003; 82: 960-5.